">
Paris-based Sanofi has decided to drop ongoing Phase 3 clinical trials and marketing rights of Hanmi Pharmaceutical’s efpeglenatide, a diabetes drug.
Lim Sung-ki, founder and chairman of Hanmi Pharmaceutical, one of Korea’s top drugmakers, passed away on the early morning of Aug. 2 at the age of 80 from chronic illness.
Paris-based Sanofi is seeking an exit from a deal with Hanmi Pharmaceutical involving global marketing rights to efpeglenatide, a diabetes drug. Shares of Kospi-listed Hanmi fell almost 10 percent on the news.
Korea JoongAng Daily Sitemap